Valneva in the news

The document details Valneva SE's debt-to-assets ratio, with data from FactSet Research Systems Inc. and copyright by the American Bankers Association.

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes vaccines for various infectious diseases, with products and candidates targeting illnesses such as Japanese encephalitis, cholera, chikungunya, Lyme disease, and Zika.

Valneva's stock saw a 3.29% increase despite remaining below its moving averages, while the company confirmed its 2026 outlook and expects regulatory decisions for its Lyme disease vaccine within the next 12 months.

Valneva's stock saw a 3.29% rise but remains below key moving averages, with the company confirming its 2026 outlook despite travel impacts on vaccine sales and awaiting regulatory decisions for its Lyme disease vaccine.

Valneva's stock rose 2.67% on the SBF 120, reaching •2.60, but remains below key moving averages and has declined over the past week and month, despite confirming its 2026 outlook.

Valneva's stock price rebounded by 2.67% to –2.60, placing it among the top SBF 120 gainers, despite recent declines and trading below key moving averages.

Valneva's stock price traded at –2.86 on September 16, 2026, following the EMA's validation of its Lyme disease vaccine application, despite a first-half net loss of –63.3 million.

Valneva's stock price experienced a significant decline, falling below key support levels, despite the company confirming its 2026 outlook amidst geopolitical challenges and expecting improved margins in the second half.

Valneva reported a 37% revenue drop in Q1 2026, prompting a reduced full-year forecast and workforce cuts, while maintaining confidence in its Lyme vaccine.

Valneva's stock experienced a significant decline, falling below key support levels amidst negative technical indicators, though the company maintains its 2026 financial guidance.

Valneva SE's stock significantly decreased by 3.06% in Paris, continuing a negative trend over the past week and year.

Valneva's stock fell below key support levels, and the company maintains a cautious revenue outlook for 2026 while awaiting regulatory decisions on its Lyme disease vaccine.

Valneva SE's stock dropped by 3.65% to  2.611, with 352,536 shares traded, and has fallen by 47.74% over the past year.

Valneva's stock price dropped to •2.64, breaking key support levels, amid cautious 2026 guidance and anticipation of Lyme disease vaccine regulatory decisions.

A user on a stock forum is concerned about Valneva's stock price, anticipating a Harami Nagazaki pattern and a potential drop to 2.4 if moving averages reset.

Valneva's stock rebounded 2% to —2.74, contributing to a 24% quarterly gain, despite being down over 40% annually and facing mixed technical indicators as it aims for its —147.5 million 2026 revenue target.

Valneva's stock has shown strong quarterly performance, gaining nearly 24%, despite recent short-term fluctuations and a significant annual loss.

The document provides a technical stock analysis for Valneva, suggesting two possible weekly candlestick patterns before the 9/7 moving average crossover.

Valneva SE is a specialty vaccine company developing and commercializing prophylactic vaccines for infectious diseases and has a diverse pipeline of vaccine candidates.

Valneva's stock has declined by 8% over the past month, trading below its 20-day moving average, despite positive quarterly results, due to operational risks and a cautious outlook for 2026.